Bromocriptine: does this drug of Parkinson’s disease have a role in managing cardiovascular diseases?
Open Access
- 19 December 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (2) , 926-929
Abstract
Cardiovascular disease (CVD) is the most common cause of morbidity and mortality worldwide. Bromocriptine is a partial antagonist for D1 dopamine receptors while also serving as a selective agonist on D2 dopamine receptors as a dopamine receptor agonist. Apart from prolactin inhibiting action, bromocriptine has some beneficial effects on the blood pressure, plasma norepinephrine levels and vascular resistance. Dopamine D2 receptor activation of bromocriptine is associated with the antihypertensive effect, which lowers blood pressure via inhibiting sympathetic nerve activity and Na/K ATPase activity. Plasma levels of the pro-inflammatory cytokines such as interleukin (IL)-1B and IL-18, chemokine CCL2/ MCP-1/, and the pro-inflammatory hormone prolactin, all of which are elevated and linked to accelerated cardiometabolic illness, were decreased because of bromocriptine therapy. The most common side effects of Bromocriptine use are dizziness, nausea, headache, vomiting and hypotension. Bromocriptine is mainly contraindicated in patients with syncope with hypotension, psychosis, and type I diabetes mellitus. The authors suggest that developing therapies directed to increase D2 receptor expression and function by drugs like Bromocriptine can provide practical and novelistic approaches to prevent and manage myocardial and renal injury in the cardiovascular disease patients.Keywords
This publication has 26 references indexed in Scilit:
- An Integrated System Biology Approach Yields Drug Repositioning Candidates for the Treatment of Heart FailureFrontiers in Genetics, 2019
- Autonomic Nervous System DysfunctionJACC, 2019
- The Effect of Bromocriptine on Left Ventricular Functional Recovery in Peripartum Cardiomyopathy: Insights from the BRO-HF Retrospective Cohort StudyESC Heart Failure, 2018
- One-Year Cardiovascular Outcomes in Patients With Peripartum CardiomyopathyJournal of Cardiac Failure, 2018
- Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetesEndocrinology, Diabetes & Metabolism, 2018
- Bromocriptine for the Treatment of Peripartum CardiomyopathyCardiac Failure Review, 2018
- Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metforminPostgraduate Medicine, 2016
- Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes SubjectsJournal of the American Heart Association, 2012
- Bromocriptine use and the risk of valvular heart diseaseMovement Disorders, 2009
- Centrally Mediated Effects of Bromocriptine on Cardiac Sympathovagal BalanceHypertension, 2001